Envisagenics’ Post

« The biotech industry thrives on partnerships, as they help to drive innovation through the sharing of knowledge, expertise, and resources. There are many different types of biotech partnerships on offer, each with its own advantages and disadvantages. Which type of partnership a company goes for is very much dependent on both its individual needs and also how much independence it wants. In this article, we take a look at eight different types of biotech partnerships. To give us some guidance, we spoke to three industry experts who explained what each one entails. » By Willow Shah Neville, Labiotech, July 2024

🎉 Exciting News! We are thrilled to announce that Altorfer Engineering GmbH has joined the Swiss Biotech Association! 🚀 As we are in a start-up mode, being part of the Swiss Biotech Association is critical to fostering innovation, collaboration, and advancement within the biotech industry. Altorfer Engineering GmbH's expertise in aseptic drug process development, technology transfer and commitment to execution excellence will undoubtedly contribute to the innovative ecosystem of the Swiss Biotech community. 💡 While the biotech communities continue to push the boundaries of science and technology, this membership shall make process development and technology transfer expertise more accessible to the communities that are getting ready for clinical or commercial manufacturing. We aim to accelerate your molecule to market time and improve healthcare by providing aseptic processing and engineering expertise to move your innovation to the next level. #Biotech #Innovation #Collaboration #SwissBiotechAssociation #AltorferEngineering #Aseptic #DrugProduct #Vaccines https://lnkd.in/dPpjTcBZ

"The Power of Collaboration: Fueling Success in a Connected World" In an era defined by connectivity and rapid change, collaboration emerges as an essential part of success. By uniting diverse talents, resources, and perspectives, we unlock a wealth of opportunities and accelerate progress. Embracing collaboration isn't just about achieving individual goals; it's about amplifying our collective impact and shaping a brighter future together. Let's harness the power of collaboration to drive innovation, foster growth, and create meaningful change. Together, we can achieve more than we ever thought possible. At ZUNF MEDICARE and NWZ-OFFICIAL, we are open to Collaborations with different Organizations, Pharmaceutical industries, Universities, and Medical Societies. Let's connect together to make a change together in this world. #Collaboration #Innovation #Success #TogetherWeCan

Another insightful talk by my longstanding colleague (and former boss) and friend, and industry luminary, Ed Saltzman!

Want to learn more about the impact of the #TPP? Learn about the Target Product Profile as an instrument when discussing partnerships and collaboration opportunities. Join the program through the link below to learn more. #mycompany #jnjinnovation

For an Aggregate of $295M, Roche to Acquire LumiraDx's Point of Care Technology #roche #lumiradx #pointofcaretechnology #mergersandacquisitions #agreement #collaboration #mid2024 #rochediagnostics #acquisition #uk #immunoassay #clinicalchemistrytests

Future-proof partners deliver tangible results, not just buzzwords. In this POV, Faruk Capan, Chief Innovation Officer, EVERSANA and CEO, EVERSANA INTOUCH, shares how intentional innovation can transform the patient and product lifecycle today, so pharma can invent life-changing therapies for tomorrow. Read more: https://ow.ly/4zf850QQqBi #PharmaInnovation #RealImpact

🌐 Upcoming Panel: Driving Innovation in Pharma Alliances Next week I'll join a panel discussion at the 14th Edition of Strategic Alliance Management for Pharma by marcus evans Summits. We'll focus on how collaboration and knowledge sharing can boost performance and innovation in the pharma industry. My perspective will be to discuss how to identify and leverage the hidden organizational levers. What will be your focus Julie Edwards, Markus Kropf, Patrick Gliha, and Lasse Funch Jacobsen? 🌊 See you there! #Innovation #StrategicAlliances #marcusevans

Taking the pulse of the Biotech community is always invigorating. BIO meetings serve as ideal platforms to assess the landscape through various channels: one-on-one partnering meetings, networking in the exhibition hall, and attending conferences. In Barcelona last week, there was a palpable sense of optimism compared to previous years. Now, there's a widespread recognition that the bar for success in the biotech community has been raised. Attention and funding are now reserved for endeavors showcasing exceptional science and robust development. Down the value chain, stakeholders increasingly agree that true value emerges when innovation becomes accessible to patients. While this may seem obvious, for years, there was an implicit assumption that the journey ended with the completion of clinical programs or an IPO. Many clinical-stage biotechs delegated this aspect to established pharmas with excuses like "Not my business" or "too complicated." Consequently, they failed to realize the full value of their assets, resulting in lower financial returns, limited medical insights, and minimal patient feedback. Giving access to patients supposes to have a strategy up to patient, i.e. a go-to-market strategy. It supposes also to have the right capabilities availables to execute the plan. The later is most challenging part. It's time for a fresh perspective! Xcube.bio focuses on European market-entry for late-stage biopharma. Its value proposition brings down the risk and cost of European set up through a unique blend of financial engineering, equity and deep-tech enablers. Ultimately, we deliver a functioning European entity with sustainable revenue stream to Biopharma partners. Visit us https://xcube.bio #biopharma, #emergingbiopharma, #launch, #incubator